---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-030924"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:26:01.593889+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Novavax Q1 revenue $140M, net loss $9M; Pfizer Matrix-M deal adds $30M upfront

## Summary
- Total revenue $140M, down 79% YoY; prior-year included $603M non-cash APA close-out.
- Net loss $9M vs net income $519M in Q1 2025; cash $795M, up from $751M.
- Pfizer non-exclusive Matrix-M license yielded $30M upfront, potential milestones up to $500M.
- Matrix-M partnering expanded: four top-10 pharma companies exploring over 30 fields; new MTAs signed.
- FY 2026 guidance reiterated: Non-GAAP combined R&D+SG&A $310-340M; cash position strengthened by $330M credit facility.

## SEC filing metadata
- accession: 0001628280-26-030924
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/0001628280-26-030924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/nvax-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-030924
- JSON: https://secwatch.observer/filing/0001628280-26-030924.json
- Plain text: https://secwatch.observer/filing/0001628280-26-030924.txt

## Key facts
- Earnings Releases
  NOVAVAX INC reported the first quarter ended March 31, 2026 results: revenue Total revenue of $140 million in the first quarter of 2026. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2026
  - Revenue: Total revenue of $140 million in the first quarter of 2026
  - Guidance: reaffirmed
  - Result: reported results
  source text: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights • Total revenue of $140 million in the first quarter of 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/0001628280-26-030924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.